Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18681291 | 0.84 | SMN1; SMN2 (0.30) | SMN1; SMN2 | |
| SCHEMBL25139835 | 0.82 | CYP1A2 (0.46) | CYP1A2CYP19A1ALDH1A1 | |
| SCHEMBL30505617 | 0.80 | ALDH1A1 (0.42) | CYP1A2SMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL7697974 | 0.78 | KEAP1 (0.42) | CYP1A2ALDH1A1HSD17B10 | |
| SCHEMBL2633369 | 0.77 | ALDH1A1 (0.43) | SMN1; SMN2KDM4EALDH1A1HPGDHSD17B10 | |
| Bromide SCHEMBL28900199 | 0.77 | KEAP1 (0.41) | CYP1A2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL18681292 | 0.76 | GLS (0.40) | KDM4EHPGD | |
| SCHEMBL29317119 | 0.75 | NOS3 (0.40) | SMN1; SMN2 | |
| SCHEMBL8606227 | 0.75 | ALOX5 (0.43) | — | |
| SCHEMBL27361633 | 0.73 | MAPT (0.40) | SMN1; SMN2KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10703733-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190352271-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2019-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352271-A1 | MCL-1 INHIBITORS | MCL1, BCL2L1, BCL2 | CYP1A2 4744/4885CYP19A1 4463/4885SMN1; SMN2 1771/4885 |
| US-10703733-B2 | MCL-1 inhibitors | MCL1, BCL2L1, BCL2 | CYP1A2 4744/4885CYP19A1 4463/4885SMN1; SMN2 1771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.